Company intelligence / Profile preview

DCprime

Ownership: Private
Development stage: Phase 2

Overview

DCprime developed a proprietary off-the-shelf allogeneic dendritic cell vaccine platform called DCOne™, with its lead product DCP‑001 reaching Phase I/IIa trials for AML. The company also had preclinical programs targeting solid tumors using peptide-loaded versions of its core technology. In December 2020, it merged with Immunicum AB to form a leader in allogeneic dendritic cell biology and cancer immunotherapy.

Therapeutic areas: Oncology
Modalities: Dendritic cell-based vaccinesCell therapyPeptide-loaded vaccines
Industry: Biotech

Beyond the preview

Go deeper on DCprime.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DCprime.

Explore the full profile